Table 1 Baseline demographic and clinical characteristics
All patients (N = 89) | Group A1 (N = 45) | Group B1 (N = 44) | p-value | |
|---|---|---|---|---|
Age, years, mean (SD) | 49.4 (13.2) | 49.7 (14.2) | 48.8 (12.3) | 0.746 |
≤ 60, n (%) | 69 (77.5) | 35 (77.8) | 34 (77.3) | 0.954 |
> 60, n (%) | 20 (22.5) | 10 (22.2) | 10 (22.7) | |
Sex, n (%) | ||||
Female | 23 (25.8) | 12 (26.7) | 11 (25.0) | 0.857 |
Male | 66 (74.2) | 33 (73.3) | 33 (75.0) | |
Ethnicity, n (%) | ||||
Greek | 82 (92.1) | 44 (97.8) | 38 (86.4) | 0.058 |
Other | 7 (7.9) | 1 (2.2) | 6 (13.6) | |
BMI, kg/m2, mean (SD) | 30 (5.7) | 29.4 (4.5) | 30.4 (6.6) | 0.4 |
< 30, n (%) | 50 (56.2) | 26 (57.8) | 24 (53.3) | 0.759 |
≥ 30, n (%) | 39 (43.8) | 19 (42.2) | 20 (46.7) | |
Smoking status, n (%) | ||||
Never | 60 (67.4) | 29 (64.4) | 31 (70.5) | 0.545 |
Former | 19 (20.3) | 11 (24.4) | 8 (18.2) | 0.714 |
Current | 10 (11.2) | 5 (11.1) | 5 (11.4) | |
Comorbidities, n (%) | ||||
Hypertension | 19 (21.3) | 9 (20.0) | 10 (22.7) | 0.754 |
Dyslipidemia | 17 (19.1) | 7 (15.6) | 10 (22.7) | 0.39 |
Diabetes | 8 (9.0) | 4 (8.9) | 4 (9.1) | > 0.999 |
CAD | 3 (3.4) | 3 (6.7) | 0 | 0.242 |
Atrial fibrillation | 3 (3.4) | 2 (4.4) | 1 (2.3) | > 0.999 |
COPD | 2 (2.2) | 2 (4.4) | 0 | 0.494 |
CKD | 1 (1.1) | 1 (2.2) | 0 | > 0.999 |
Known immunosuppression | 0 | 0 | 0 | - |
Score on NIAID-OS, n (%) | ||||
4 | 6 (6.7) | 3 (6.7) | 3 (6.8) | |
5 | 65 (73.0) | 32 (71.1) | 33 (75.0) | 0.893 |
6 | 18 (20.3) | 10 (22.2) | 8 (18.2) | |
Concomitant medication, n (%) | ||||
Antibiotics | 57 (64.0) | 29 (64.4) | 28 (63.6) | 0.726 |
Remdesivir | 75 (84.3) | 38 (84.4) | 37 (84.1) | > 0.999 |
Dexamethasone | 75 (84.3) | 39 (86.7) | 36 (81.8) | 0.56 |
Baricitinib | 14 (15.9) | 8 (18.2) | 6 (13.6) | 0.56 |
Tocilizumab | 8 (9.0) | 5 (11.1) | 3 (6.8) | 0.694 |
Anticoagulants | ||||
Prophylactic | 58 (66.7) | 29 (65.9) | 29 (67.4) | 0.879 |
Intermediate | 23 (26.4) | 10 (22.7) | 13 (30.2) | 0.427 |
Therapeutic | 8 (9.2) | 6 (13.6) | 2 (4.7) | 0.147 |